Mifepristone manufacturers Danco Laboratories and another company filed an emergency petition with the Supreme Court on Saturday seeking to block a Fifth Circuit ruling that requires the abortion pill be dispensed only in person. Louisiana brought the original lawsuit that prompted the appeals court decision reinstating the in-person dispensing requirement. The case, Danco Laboratories v. Louisiana, returns to the nation's highest court as the manufacturers argue against restrictions on how the drug reaches patients. The Fifth Circuit's ruling represents a significant setback for access to medication abortion, which the FDA previously approved for mail delivery under specific conditions. The manufacturers' emergency request asks the justices to pause the appellate court's decision, effectively halting the in-person requirement while the broader legal dispute continues. This marks another chapter in ongoing litigation over mifepristone's availability following the Supreme Court's 2022 decision to overturn Roe v. Wade. The case highlights the collision between state-level abortion restrictions and federal drug approval standards.